Astrazeneca to hold additional global trial for its COVID-19 vaccine as questions mount
- 3 years ago
백신 효과 논란에…아스트라제네카 “추가 글로벌 임상시험 추진”
Astrazeneca is planning an additional global trial for its COVID-19 vaccine candidate to clear up any lingering uncertainties.
The company's CEO said Thursday that an additional study is needed to validate the 90-percent efficacy rate shown in a portion of an existing trial.
However, the new test is not expected to hold up approvals in the U.K. or the EU.
Questions have been mounting after the company and its partner Oxford University,... acknowledged their trial results might've been affected by an error.
Astrazeneca is planning an additional global trial for its COVID-19 vaccine candidate to clear up any lingering uncertainties.
The company's CEO said Thursday that an additional study is needed to validate the 90-percent efficacy rate shown in a portion of an existing trial.
However, the new test is not expected to hold up approvals in the U.K. or the EU.
Questions have been mounting after the company and its partner Oxford University,... acknowledged their trial results might've been affected by an error.